Overview

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

Status:
Completed

Trial end date:
2016-12-31

Target enrollment:

Participant gender:

Summary

The aim of this study is to assess the real world comparative effectiveness of Rivaroxaban prescribed in non-valvular atrial fibrillation (NVAF) routine care patients in Germany.

Details

Lead Sponsor:

Bayer

Collaborator:

Janssen Research & Development, LLC

Treatments:

Phenprocoumon
Rivaroxaban
Vitamin K